FI2794907T4 - Menetelmiä ja materiaaleja heterotsygoottisuuden menettämisen arvioimiseksi - Google Patents
Menetelmiä ja materiaaleja heterotsygoottisuuden menettämisen arvioimiseksi Download PDFInfo
- Publication number
- FI2794907T4 FI2794907T4 FIEP12860530.0T FI12860530T FI2794907T4 FI 2794907 T4 FI2794907 T4 FI 2794907T4 FI 12860530 T FI12860530 T FI 12860530T FI 2794907 T4 FI2794907 T4 FI 2794907T4
- Authority
- FI
- Finland
- Prior art keywords
- cancer
- human
- loh
- cancer cell
- loh regions
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 11
- 201000011510 cancer Diseases 0.000 claims 34
- 206010028980 Neoplasm Diseases 0.000 claims 29
- 210000004027 cell Anatomy 0.000 claims 18
- 210000003917 human chromosome Anatomy 0.000 claims 12
- 210000000349 chromosome Anatomy 0.000 claims 8
- 239000012623 DNA damaging agent Substances 0.000 claims 7
- 239000012661 PARP inhibitor Substances 0.000 claims 7
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 claims 7
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 7
- 206010006187 Breast cancer Diseases 0.000 claims 5
- 208000026310 Breast neoplasm Diseases 0.000 claims 5
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 claims 5
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 5
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 5
- 206010033128 Ovarian cancer Diseases 0.000 claims 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 5
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 claims 5
- 201000004101 esophageal cancer Diseases 0.000 claims 5
- 201000005202 lung cancer Diseases 0.000 claims 5
- 208000020816 lung neoplasm Diseases 0.000 claims 5
- 210000003765 sex chromosome Anatomy 0.000 claims 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 4
- 230000005855 radiation Effects 0.000 claims 4
- 108091034117 Oligonucleotide Proteins 0.000 claims 3
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical group O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 2
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 2
- -1 anthracyclines Substances 0.000 claims 2
- 229940127093 camptothecin Drugs 0.000 claims 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical group C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 2
- 238000004590 computer program Methods 0.000 claims 2
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims 2
- 229960003668 docetaxel Drugs 0.000 claims 2
- 229960004679 doxorubicin Drugs 0.000 claims 2
- 229960001904 epirubicin Drugs 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 229960004768 irinotecan Drugs 0.000 claims 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 2
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical group FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 claims 2
- 229960000572 olaparib Drugs 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 229960000303 topotecan Drugs 0.000 claims 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 238000011269 treatment regimen Methods 0.000 claims 2
- 102000003915 DNA Topoisomerases Human genes 0.000 claims 1
- 108090000323 DNA Topoisomerases Proteins 0.000 claims 1
- 238000009007 Diagnostic Kit Methods 0.000 claims 1
- 101710183280 Topoisomerase Proteins 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 190000008236 carboplatin Chemical compound 0.000 claims 1
- 229940044683 chemotherapy drug Drugs 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 1
- IIMIOEBMYPRQGU-UHFFFAOYSA-L picoplatin Chemical compound N.[Cl-].[Cl-].[Pt+2].CC1=CC=CC=N1 IIMIOEBMYPRQGU-UHFFFAOYSA-L 0.000 claims 1
- 229950005566 picoplatin Drugs 0.000 claims 1
- 238000011518 platinum-based chemotherapy Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/10—Ploidy or copy number detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Inorganic Chemistry (AREA)
- Theoretical Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Medical Informatics (AREA)
- Evolutionary Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161578713P | 2011-12-21 | 2011-12-21 | |
| US201261654402P | 2012-06-01 | 2012-06-01 | |
| PCT/US2012/071380 WO2013096843A1 (en) | 2011-12-21 | 2012-12-21 | Methods and materials for assessing loss of heterozygosity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI2794907T4 true FI2794907T4 (fi) | 2023-03-27 |
Family
ID=48669561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP12860530.0T FI2794907T4 (fi) | 2011-12-21 | 2012-12-21 | Menetelmiä ja materiaaleja heterotsygoottisuuden menettämisen arvioimiseksi |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US9388472B2 (enExample) |
| EP (3) | EP3660161B1 (enExample) |
| JP (5) | JP6325453B2 (enExample) |
| CN (2) | CN104160037B (enExample) |
| AU (4) | AU2012358244A1 (enExample) |
| BR (1) | BR112014015152A2 (enExample) |
| CA (1) | CA2860312C (enExample) |
| DK (1) | DK2794907T4 (enExample) |
| ES (1) | ES2759533T5 (enExample) |
| FI (1) | FI2794907T4 (enExample) |
| WO (1) | WO2013096843A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011160063A2 (en) | 2010-06-18 | 2011-12-22 | Myriad Genetics, Inc. | Methods and materials for assessing loss of heterozygosity |
| ES2704303T3 (es) | 2010-08-24 | 2019-03-15 | Dana Farber Cancer Inst Inc | Procedimientos para la predicción de una respuesta contra el cáncer |
| CA2839210A1 (en) | 2011-06-17 | 2012-12-20 | Myriad Genetics, Inc. | Methods and materials for assessing allelic imbalance |
| EP3660161B1 (en) * | 2011-12-21 | 2024-07-31 | Myriad Genetics, Inc. | Methods and materials for assessing loss of heterozygosity |
| EP3415915B1 (en) | 2012-02-23 | 2024-10-23 | Children's Medical Center Corporation | Methods for predicting response to parp inhibitors |
| CA2867434C (en) | 2012-06-07 | 2021-10-12 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
| EP4023765A1 (en) | 2013-12-09 | 2022-07-06 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
| CN105917007A (zh) * | 2014-01-16 | 2016-08-31 | 克洛维斯肿瘤有限公司 | Parp抑制剂用以治疗显示杂合性丧失的乳腺癌或卵巢癌患者的用途 |
| ES2800673T3 (es) | 2014-08-15 | 2021-01-04 | Myriad Genetics Inc | Métodos y materiales para evaluar una deficiencia de recombinación homóloga |
| US20160160294A1 (en) * | 2014-12-08 | 2016-06-09 | Tesaro | Methods and materials for predicting response to niraparib |
| US20180148792A1 (en) | 2015-05-19 | 2018-05-31 | T.S. Sridhar | Method for Identification of a Deficient BRCA1 Function |
| WO2017191074A1 (en) * | 2016-05-01 | 2017-11-09 | Genome Research Limited | Method of characterising a dna sample |
| GB201607629D0 (en) * | 2016-05-01 | 2016-06-15 | Genome Res Ltd | Mutational signatures in cancer |
| WO2017191076A1 (en) * | 2016-05-01 | 2017-11-09 | Genome Research Limited | Method of characterising a dna sample |
| GB2555765A (en) | 2016-05-01 | 2018-05-16 | Genome Res Ltd | Method of detecting a mutational signature in a sample |
| CN107287285A (zh) * | 2017-03-28 | 2017-10-24 | 上海至本生物科技有限公司 | 一种预测同源重组缺失机制及患者对癌症治疗响应的方法 |
| US11830579B2 (en) | 2017-07-25 | 2023-11-28 | Sophia Genetics Sa | Methods for detecting biallelic loss of function in next-generation sequencing genomic data |
| CN112805563B (zh) * | 2018-05-18 | 2025-06-13 | 约翰·霍普金斯大学 | 用于评估和/或治疗癌症的无细胞dna |
| IT201900013335A1 (it) * | 2019-07-30 | 2021-01-30 | Menarini Silicon Biosystems Spa | Metodo per analizzare la perdita di eterozigosi (loh) a seguito di amplificazione totale del genoma basata su un sito di restrizione deterministico (drs-wga) |
| EP4051805A4 (en) * | 2019-10-29 | 2023-11-01 | The Board of Trustees of the Leland Stanford Junior University | TREATMENT METHODS BASED ON MOLECULAR RESPONSE TO TREATMENT |
| EP3945525A1 (en) | 2020-07-27 | 2022-02-02 | Sophia Genetics S.A. | Methods for identifying chromosomal spatial instability such as homologous repair deficiency in low coverage next-generation sequencing data |
| CN112410423B (zh) * | 2020-11-03 | 2021-08-13 | 南京世和基因生物技术股份有限公司 | 同源重组缺失的标志物、检测方法以及检测系统 |
| CN112226495B (zh) * | 2020-12-18 | 2021-03-16 | 北京迈基诺基因科技股份有限公司 | 一种dna同源重组异常的检测方法及其应用 |
| EP4274908A1 (en) * | 2021-01-10 | 2023-11-15 | Act Genomics (IP) Limited | Homologous recombination deficiency determining method and kit thereof |
| WO2022150063A1 (en) * | 2021-01-10 | 2022-07-14 | Act Genomics (Ip) Co., Ltd. | Homologous recombination deficiency determining method and kit thereof |
| CN113466417B (zh) * | 2021-05-13 | 2023-03-21 | 柳州东风容泰化工股份有限公司 | 一种氟尿嘧啶的制备纯度评估方法及系统 |
| US12188961B2 (en) | 2022-07-29 | 2025-01-07 | International Business Machines Corporation | Method for accurate pad contact testing |
| EP4605937A1 (en) | 2022-10-19 | 2025-08-27 | Vib Vzw | Method of determining loss of heterozygosity status of a tumor |
| WO2025078387A1 (en) | 2023-10-10 | 2025-04-17 | Vib Vzw | Method of detecting loss of heterozygosity status of a tumor |
| WO2025078404A1 (en) | 2023-10-10 | 2025-04-17 | Vib Vzw | Methods of determining response of a tumor to dna-damaging agents or to agents inhibiting or impairing dna repair |
| WO2025173014A1 (en) | 2024-02-16 | 2025-08-21 | Onecell Diagnostics India Private Limited | A method for selecting ovarian cancer patients for parp inhibitor treatment |
Family Cites Families (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| YU33730B (en) | 1967-04-18 | 1978-02-28 | Farmaceutici Italia | Process for preparing a novel antibiotic substance and salts thereof |
| GB1432563A (en) | 1972-04-10 | 1976-04-22 | Rustenburg Platinum Mines Ltd | Platinum- co-ordination compounds |
| GB1432562A (en) | 1972-04-10 | 1976-04-22 | Rustenburg Platinum Mines Ltd | Platinum co-ordination compounds |
| ES444380A1 (es) | 1976-01-16 | 1977-06-16 | Gosalvez Mario | Un procedimiento para preparar derivados metalicos antraci- clinicos. |
| US4950738A (en) | 1984-09-13 | 1990-08-21 | Cytogen Corporation | Amine derivatives of anthracycline antibiotics |
| US5977082A (en) | 1985-08-02 | 1999-11-02 | Pharmacia & Upjohn Company | Injectable ready-to-use solutions containing an antitumor anthracycline glycoside |
| DE3630497A1 (de) | 1986-09-08 | 1988-03-10 | Behringwerke Ag | Cis-platin-komplexe, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische mittel |
| DK252688A (da) | 1987-05-08 | 1988-11-09 | Sankyo Co | Antitumorplatinkomplekser, fremgangsmaade til fremstilling deraf, samt deres terapeutiske anvendelse |
| US4996337A (en) | 1987-06-23 | 1991-02-26 | American Cyanamid Company | Synthesis of cisplatin analogs |
| US5177075A (en) | 1988-08-19 | 1993-01-05 | Warner-Lambert Company | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process |
| US5434256A (en) | 1988-11-22 | 1995-07-18 | Board Of Regents, The University Of Texas System | Diamine platinum complexes as antitumor agents |
| US4946954A (en) | 1989-01-17 | 1990-08-07 | Georgetown University | Platinum pharmaceutical agents |
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| AU647741B2 (en) | 1989-12-01 | 1994-03-31 | Regents Of The University Of California, The | Methods and compositions for chromosome-specific staining |
| US5295944A (en) | 1991-05-14 | 1994-03-22 | Dana-Farber Cancer Institute | Method for treating a tumor with ionizing radiation |
| MX9206577A (es) | 1991-11-15 | 1993-05-01 | Smithkline Beecham Corp | COMPOSICIóN FARMACEUTICA PARA INHIBIR EL CRECIMIENTO DE CELULAS TUMORALES |
| WO1995003335A1 (en) * | 1993-07-26 | 1995-02-02 | K.O. Technology, Inc. | Inhibitors of alternative alleles of genes as a basis for cancer therapeutic agents |
| US5587384A (en) | 1994-02-04 | 1996-12-24 | The Johns Hopkins University | Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity |
| US5578832A (en) | 1994-09-02 | 1996-11-26 | Affymetrix, Inc. | Method and apparatus for imaging a sample on a device |
| US5539083A (en) | 1994-02-23 | 1996-07-23 | Isis Pharmaceuticals, Inc. | Peptide nucleic acid combinatorial libraries and improved methods of synthesis |
| US5556752A (en) | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
| US5837492A (en) | 1995-12-18 | 1998-11-17 | Myriad Genetics, Inc. | Chromosome 13-linked breast cancer susceptibility gene |
| GB9620209D0 (en) | 1996-09-27 | 1996-11-13 | Cemu Bioteknik Ab | Method of sequencing DNA |
| GB9626815D0 (en) | 1996-12-23 | 1997-02-12 | Cemu Bioteknik Ab | Method of sequencing DNA |
| WO1998041531A2 (en) | 1997-03-20 | 1998-09-24 | University Of Washington | Solvent for biopolymer synthesis, solvent microdroplets and methods of use |
| US6214821B1 (en) | 1998-03-05 | 2001-04-10 | Washington State University Research Foundation | Methods and composition for the inhibition of cancer cells |
| GB9806324D0 (en) | 1998-03-24 | 1998-05-20 | Pharmacia & Upjohn Spa | Antitumour synergetic composition |
| GB9808145D0 (en) | 1998-04-17 | 1998-06-17 | Zeneca Ltd | Assay |
| US20030049613A1 (en) | 1998-08-17 | 2003-03-13 | Manuel Perucho | Methods for identifying somatic changes in genomic sequences useful for cancer diagnosis and prognosis |
| US6465177B1 (en) | 1998-10-26 | 2002-10-15 | John Wayne Cancer Institute | Detection of loss of heterozygosity in tumor and serum of melanoma patients |
| WO2000040755A2 (en) | 1999-01-06 | 2000-07-13 | Cornell Research Foundation, Inc. | Method for accelerating identification of single nucleotide polymorphisms and alignment of clones in genomic sequencing |
| US6261775B1 (en) | 1999-04-09 | 2001-07-17 | The Regents Of The University Of California | Detection of chromosome copy number changes to distinguish melanocytic nevi from malignant melanoma |
| US6274320B1 (en) | 1999-09-16 | 2001-08-14 | Curagen Corporation | Method of sequencing a nucleic acid |
| US6858412B2 (en) | 2000-10-24 | 2005-02-22 | The Board Of Trustees Of The Leland Stanford Junior University | Direct multiplex characterization of genomic DNA |
| US7858331B2 (en) | 2000-11-03 | 2010-12-28 | Dana Farber Cancer Institute, Inc. | Compositions and methods for the treatment of cancer |
| ATE478664T1 (de) | 2000-12-01 | 2010-09-15 | Eisai Inc | Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren |
| GB0121285D0 (en) | 2001-09-03 | 2001-10-24 | Cancer Res Ventures Ltd | Anti-cancer combinations |
| CA2477761A1 (en) | 2002-03-01 | 2003-09-12 | Ravgen, Inc. | Methods for detection of genetic disorders |
| US20050191632A1 (en) | 2002-11-01 | 2005-09-01 | John Byrd | Cytogenetic abnormalities that are predictive of response to therapy for chronic lymphocytic leukemia |
| WO2004072269A2 (en) | 2003-02-12 | 2004-08-26 | Mayo Foundation For Medical Education And Research | Bex4 nucleic acids, polypeptides, and method of using |
| US20040170983A1 (en) * | 2003-02-27 | 2004-09-02 | Danenberg Kathleen D. | Methods of determining a chemotherapuetic regimin based on loss of heterozygosity at the thymidylate synthase locus |
| US20050112604A1 (en) | 2003-03-14 | 2005-05-26 | Akihide Fujimoto | Loss of heterozygosity of the DNA markers in the 12q22-23 region |
| US7754684B2 (en) | 2003-06-11 | 2010-07-13 | Access Pharmaceuticals, Inc. | Macromolecular platinum chelates |
| DE04777189T1 (de) | 2003-07-02 | 2011-04-07 | Solux Corporation, San Diego | Thermisch stabiles kristallines epirubicin-hydrochlorid und herstellungsverfahren dafür |
| ATE454893T1 (de) | 2003-07-25 | 2010-01-15 | Cancer Rec Tech Ltd | Tricyclische parp-hemmer |
| DE602004015811D1 (de) | 2003-08-13 | 2008-09-25 | Univ South Florida | Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden |
| US20080108057A1 (en) | 2004-06-22 | 2008-05-08 | Griffith Jeffrey K | Allelic imbalance in the diagnosis and prognosis of cancer |
| WO2006047481A2 (en) | 2004-10-22 | 2006-05-04 | Redpath Integrated Pathology, Inc. | Enhanced amplifiability of minute fixative-treated tissue samples, minute stained cytology samples, and other minute sources of dna |
| US20070070349A1 (en) | 2005-09-23 | 2007-03-29 | Helicos Biosciences Corporation | Optical train and method for TIRF single molecule detection and analysis |
| US8105768B2 (en) | 2005-03-09 | 2012-01-31 | Abbott Laboratories | Methods of identifying patients for treatment with HER-2/neu inhibitors based on detection of HER-2/neu and TOP2A gene copy number |
| US20060234264A1 (en) | 2005-03-14 | 2006-10-19 | Affymetrix, Inc. | Multiplex polynucleotide synthesis |
| JP2008538496A (ja) | 2005-04-12 | 2008-10-30 | ４５４ ライフ サイエンシーズ コーポレイション | ウルトラディープ配列決定を用いて配列変異体を決定するための方法 |
| AU2006238877A1 (en) | 2005-04-21 | 2006-11-02 | Alza Corporation | Method for treating advanced ovarian cancer with doxorubicin entrapped in liposomes |
| WO2006128195A2 (en) | 2005-05-27 | 2006-11-30 | Dana-Farber Cancer Institute | Methods of diagnosing and treating cancer by detection of chromosomal abnormalities |
| MX2007015852A (es) | 2005-06-30 | 2008-02-22 | Bionumerik Pharmaceuticals Inc | Analogos de platino con ligandos de monoazol. |
| EP1926835B1 (en) | 2005-09-21 | 2014-12-31 | BioArray Solutions Ltd. | Message abundance and allele copy number determination using ivt with single-stranded primer-promoter-selector constructs |
| US20080262062A1 (en) | 2006-11-20 | 2008-10-23 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
| US20090081237A1 (en) | 2007-03-12 | 2009-03-26 | Dana-Farber Cancer Institute | Prognostic, diagnostic, and cancer therapeutic uses of FANCI and FANCI modulating agents |
| CN101821619B (zh) | 2007-09-07 | 2015-02-11 | 弗卢丁公司 | 拷贝数变化确定、方法和系统 |
| SI2209375T1 (sl) * | 2007-10-03 | 2014-12-31 | Eisai Inc. | Spojine inhibitorja PARP in metode uporabe |
| KR20100102609A (ko) | 2007-11-12 | 2010-09-24 | 바이파 사이언스 인코포레이티드 | Ｐａｒｐ 억제제를 단독으로 사용하거나 항종양제와 병용하여 유방암을 치료하는 방법 |
| CA2708157A1 (en) | 2007-12-07 | 2009-06-11 | Bipar Sciences, Inc. | Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors |
| US20090246789A1 (en) | 2008-03-25 | 2009-10-01 | University Of South Carolina | Gene Mutation Profiling of CSMD1 |
| WO2009148528A2 (en) | 2008-05-30 | 2009-12-10 | Millennium Pharmaceuticals, Inc. | Assessment of chromosomal alterations to predict clinical outcome of bortezomib treatment |
| CN102203787B (zh) | 2008-10-31 | 2015-08-26 | Abbvie公司 | 基于基因拷贝数改变的模式的结肠直肠癌的基因组分类 |
| US8206910B2 (en) * | 2008-12-08 | 2012-06-26 | The Cleveland Clinic Foundation | Targets for use in diagnosis, prognosis and therapy of breast cancer |
| KR100925337B1 (ko) | 2009-05-25 | 2009-11-09 | 주식회사 마크로젠 | 염색체 수 이상 검출을 통한 유방암 약물 반응성 예측 |
| WO2011048495A1 (en) | 2009-10-19 | 2011-04-28 | Stichting Het Nederlands Kanker Instituut | Predicting benefit of anti-cancer therapy via array comparative genomic hybridization |
| EP2539468A4 (en) | 2010-02-24 | 2013-08-28 | Myriad Genetics Inc | DIAGNOSTIC PROCEDURE INCLUDING LOSS OF HETEROZYGOTY |
| WO2011160063A2 (en) * | 2010-06-18 | 2011-12-22 | Myriad Genetics, Inc. | Methods and materials for assessing loss of heterozygosity |
| WO2012019000A2 (en) | 2010-08-04 | 2012-02-09 | On-Q-ity | Biomarkers for the identification monitoring and treatment of ovarian cancer |
| ES2704303T3 (es) | 2010-08-24 | 2019-03-15 | Dana Farber Cancer Inst Inc | Procedimientos para la predicción de una respuesta contra el cáncer |
| KR20190002733A (ko) | 2010-12-30 | 2019-01-08 | 파운데이션 메디신 인코포레이티드 | 종양 샘플의 다유전자 분석의 최적화 |
| CA2839210A1 (en) | 2011-06-17 | 2012-12-20 | Myriad Genetics, Inc. | Methods and materials for assessing allelic imbalance |
| EP3660161B1 (en) * | 2011-12-21 | 2024-07-31 | Myriad Genetics, Inc. | Methods and materials for assessing loss of heterozygosity |
| EP3415915B1 (en) | 2012-02-23 | 2024-10-23 | Children's Medical Center Corporation | Methods for predicting response to parp inhibitors |
| CA2867434C (en) | 2012-06-07 | 2021-10-12 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
| AU2014248007B2 (en) | 2013-04-05 | 2020-03-26 | Myriad Genetics, Inc. | Methods and materials for assessing homologous recombination deficiency |
| EP4023765A1 (en) | 2013-12-09 | 2022-07-06 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
| CN105917007A (zh) | 2014-01-16 | 2016-08-31 | 克洛维斯肿瘤有限公司 | Parp抑制剂用以治疗显示杂合性丧失的乳腺癌或卵巢癌患者的用途 |
| ES2800673T3 (es) * | 2014-08-15 | 2021-01-04 | Myriad Genetics Inc | Métodos y materiales para evaluar una deficiencia de recombinación homóloga |
| JP7259274B2 (ja) * | 2018-11-12 | 2023-04-18 | ソニーグループ株式会社 | 情報処理装置、情報処理方法、及びプログラム |
-
2012
- 2012-12-21 EP EP19199341.9A patent/EP3660161B1/en active Active
- 2012-12-21 DK DK12860530.0T patent/DK2794907T4/da active
- 2012-12-21 WO PCT/US2012/071380 patent/WO2013096843A1/en not_active Ceased
- 2012-12-21 BR BR112014015152A patent/BR112014015152A2/pt not_active IP Right Cessation
- 2012-12-21 ES ES12860530T patent/ES2759533T5/es active Active
- 2012-12-21 CA CA2860312A patent/CA2860312C/en active Active
- 2012-12-21 EP EP24191594.1A patent/EP4497824A3/en active Pending
- 2012-12-21 CN CN201280070358.0A patent/CN104160037B/zh active Active
- 2012-12-21 AU AU2012358244A patent/AU2012358244A1/en not_active Abandoned
- 2012-12-21 JP JP2014548965A patent/JP6325453B2/ja active Active
- 2012-12-21 CN CN201710172605.2A patent/CN107267598B/zh active Active
- 2012-12-21 EP EP12860530.0A patent/EP2794907B2/en active Active
- 2012-12-21 FI FIEP12860530.0T patent/FI2794907T4/fi active
-
2014
- 2014-06-18 US US14/307,708 patent/US9388472B2/en active Active
-
2016
- 2016-06-24 US US15/192,497 patent/US10612098B2/en active Active
-
2018
- 2018-04-12 JP JP2018076503A patent/JP6700333B2/ja active Active
- 2018-08-02 AU AU2018211277A patent/AU2018211277B2/en active Active
-
2020
- 2020-02-24 US US16/799,797 patent/US20200190602A1/en active Pending
- 2020-04-30 JP JP2020079997A patent/JP7128853B2/ja active Active
- 2020-08-28 AU AU2020223754A patent/AU2020223754B2/en active Active
-
2022
- 2022-08-19 JP JP2022130844A patent/JP7595619B2/ja active Active
- 2022-09-08 AU AU2022228167A patent/AU2022228167B2/en active Active
- 2022-12-14 US US18/081,586 patent/US20230111438A1/en active Pending
-
2024
- 2024-11-26 JP JP2024205398A patent/JP2025032160A/ja active Pending
-
2025
- 2025-03-21 US US19/087,361 patent/US20250215509A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI2794907T4 (fi) | Menetelmiä ja materiaaleja heterotsygoottisuuden menettämisen arvioimiseksi | |
| JP2015506678A5 (enExample) | ||
| ES2862331T3 (es) | Métodos para predecir el estado de los genes BRCA1 y BRCA2 en una célula de cáncer | |
| Yanaihara et al. | Unique microRNA molecular profiles in lung cancer diagnosis and prognosis | |
| Birkbak et al. | Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents | |
| Gao et al. | MiR-21 overexpression in human primary squamous cell lung carcinoma is associated with poor patient prognosis | |
| JP2016523511A5 (enExample) | ||
| ES2687024T3 (es) | Procedimientos para predecir la respuesta contra el cáncer | |
| JP2021112205A (ja) | 相同組換え欠損を評価するための方法および材料 | |
| Li et al. | Identification of intrinsic subtype-specific prognostic microRNAs in primary glioblastoma | |
| JP2010538610A5 (enExample) | ||
| Cherradi | microRNAs as potential biomarkers in adrenocortical cancer: progress and challenges | |
| JP2010516291A5 (enExample) | ||
| JP2012500389A5 (enExample) | ||
| CN101688240A (zh) | 通过微rna预测癌症患者的治疗后存活预期 | |
| Rossi et al. | MicroRNAs, ultraconserved genes and colorectal cancers | |
| Sun et al. | Screening of differently expressed miRNA and mRNA in prostate cancer by integrated analysis of transcription data | |
| US10676791B2 (en) | Methods for predicting response to DNA repair pathway inhibitors in diffuse large B-cell lymphoma | |
| Guan et al. | Identification of low miR-105 expression as a novel poor prognostic predictor for human glioma | |
| Peter et al. | A selective screening platform reveals unique global expression patterns of microRNAs in a cohort of human soft-tissue sarcomas | |
| Hernández-Sánchez et al. | MiRNA expression profile of chronic lymphocytic leukemia patients with 13q deletion | |
| Jiang et al. | Identification of a novel fusion gene (HLA-E and HLA-B) by RNA-seq analysis in esophageal squamous cell carcinoma | |
| Gosia et al. | Long Non-Coding, Micro, and Circular RNAs in Ovarian Cancer Metastasis: Pathways and Treatment Approaches | |
| Ember et al. | 562 Early Aberration of MicroRNA Expression Profile After Treatment With MNU | |
| Hirano et al. | GENE-49. Aberrant super-enhancers associated with downregulation of ret finger protein overcomes chemoresistance in glioblastoma |